The Cost-Effectiveness of Second-Line Crizotinib in Eml4-Alk Rearranged Advanced Non-Small Cell Lung Cancer
Nov 1, 2014, 00:00
10.1016/j.jval.2014.08.2321
https://www.valueinhealthjournal.com/article/S1098-3015(14)04251-X/fulltext
Title :
The Cost-Effectiveness of Second-Line Crizotinib in Eml4-Alk Rearranged Advanced Non-Small Cell Lung Cancer
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(14)04251-X&doi=10.1016/j.jval.2014.08.2321
First page :
A642
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
1776